martes, 3 de diciembre de 2013

National Guideline Clearinghouse | Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer.

full-text ► 
National Guideline Clearinghouse | Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer.

 National Institute for Health and Care Excellence (NICE)
National Guideline Clearinghouse (NGC)

December 2, 2013


Guideline Title


Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer.
 


Bibliographic Source(s)


National Institute for Health and Care Excellence (NICE). Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer. London (UK): National Institute for Health and Care Excellence (NICE); 2013 May. 44 p. (Technology appraisal guidance; no. 284). 

 
Guideline Status

This is the current release of the guideline.

No hay comentarios:

Publicar un comentario